Key result
Hemodialysis did not significantly affect the antiplatelet effects of aspirin (AA-induced inhibition 82.56% vs 86.42%, p=0.213) or clopidogrel (ADP-induced inhibition 67.87% vs 61.94%, p=0.167) in uremic patients with coronary heart disease.
Why the study?
Does hemodialysis affect the antiplatelet efficacy of aspirin and clopidogrel in uremic patients with coronary heart disease?
Observational (n=26)
No
Does hemodialysis affect the antiplatelet efficacy of aspirin and clopidogrel in uremic patients with coronary heart disease?
Absolute Event Rate: 86.42% vs 82.56%
p-value: p=0.213
Hemodialysis does not significantly alter the antiplatelet efficacy of aspirin and clopidogrel in uremic patients with coronary heart disease.
Supports stable antiplatelet regimens around hemodialysis in uremic CHD patients; hypothesis-generating and requires randomized confirmation.
BACKGROUND: Coronary intervention therapy is the main treatment for uremic patients with coronary heart disease. The studies on whether dialysis reduces the efficacy of dual antiplatelet drugs are limited. The aim of this study was to examine the effect of dialysis on antiplatelet drugs in uremic patients with coronary heart disease. METHODS: This study included 26 uremic patients who had undergone percutaneous coronary intervention in China-Japan Friendship Hospital from November 2015 to May 2017. We examined their thromboelastography results before and after hemodialysis. Self-paired t-tests were employed to analyze changes in the inhibition rate of platelet aggregation. RESULTS: The mean inhibition rates of arachidonic acid-induced platelet aggregation before and after hemodialysis were 82.56 ± 2.79% and 86.42 ± 3.32%, respectively (t= -1.278, P= 0.213). The mean inhibition rates of adenosine diphosphate-induced platelet aggregation before and after hemodialysis were 67.87 ± 5.10% and 61.94 ± 5.90%, respectively (t = 1.425, P= 0.167). There was no significant difference in the inhibition rates of platelet aggregation before or after hemodialysis. These results also applied to patients with different sensitivity to aspirin and clopidogrel. CONCLUSION: Dialysis did not affect the antiplatelet effects of aspirin and clopidogrel in uremic patients with coronary heart disease.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2017) conducted an observational in Uremic patients with coronary heart disease (n=26). Hemodialysis vs. Pre-hemodialysis was evaluated on Inhibition rate of arachidonic acid-induced platelet aggregation (p=0.213). Hemodialysis did not significantly affect the antiplatelet effects of aspirin (AA-induced inhibition 82.56% vs 86.42%, p=0.213) or clopidogrel (ADP-induced inhibition 67.87% vs 61.94%, p=0.167) in uremic patients with coronary heart disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: